We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
US biotech group is among coronavirus vaccine makers struggling with reduced demand post-pandemic
Much of the global demand for initial shots and boosters has already been met
Pharmaceutical groups to part ways with longstanding executives
US drugmaker’s shares fall more than 30% as it blames weak demand for jabs
Protein-based vaccine is an alternative to mRNA technology used by BioNTech/Pfizer and Moderna
Early clinical findings show that two-in-one shot could be safe and effective
US biotech says its shot could alleviate vaccine hesitancy and calls on government to promote it
US biotech shot authorised for primary use after repeated delays in submission to regulator
Positive early results showing ‘broad cross-reactivity’ a boost for Covax vaccine access scheme
Bloc to get its fifth vaccine shot as US biotech targets 2bn doses in 2022
US drugmaker ‘confident’ as health bodies signal decisions on the horizon
US biotech’s shares jump over hopes for shot that could be crucial for lower-income countries
Filing offers boost for Covax vaccine programme which has agreed deal for 350m doses
Biotech’s shares fall after pushing back submission of data to US regulator to the fourth quarter
Biotech ‘one step closer’ to launching shot but has yet to finalise regulatory submissions
Jab developed by University of Oxford team proves 77% effective in Burkina Faso mid-stage tests
Scientists are testing the risks and advantages of offering a different shot for second and third doses
Drugmaker will ‘fill and finish’ as-yet-unapproved jabs as talks continue over EU export controls
New vaccine producers and mRNA technology are shaking up the market
US company prepares to launch its vaccine but the road to success has been long
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
Thirty-year-old biotech is unexpected success story in race to produce Covid-19 jab
FT tracker shows rapid growth in doses administered around world — but warnings come of long road ahead
US biotech says its jab also displayed ‘significant clinical efficacy’ against two virus variants
UK Edition
